Autolus Therapeutics Announces Update on its Novel CAR T Cell Program for Peripheral T Cell Lymphoma (PTCL)
PharmiWeb,
-First patient dosed in Phase 1/2 trial of AUTO4 in TRBC1-positive peripheral T cell lymphoma- -Preclinical data for AUTO5…
-First patient dosed in Phase 1/2 trial of AUTO4 in TRBC1-positive peripheral T cell lymphoma- -Preclinical data for AUTO5…
/PRNewswire/ -- Arix Bioscience plc (LSE: ARIX) ("Arix"), a global healthcare and life science company supporting medical…
SOURCE Arix Bioscience plc LONDON Arix Bioscience plc (LSE: ARIX) ("Arix"), a global healthcare and life science company…
SOURCE Arix Bioscience plc LONDON Arix Bioscience plc (LSE: ARIX) ("Arix"), a global healthcare and life science company…